The post-PR change in SPARC mRNA expression was significantly greater in nonatrophic compared to atrophic patients with COPD (supplementary figure S1d), and these changes were negatively associated with type II CSA (rs = −0.68, p=0.030) (supplementary table S1). The gene discussed is SPARC; the disease is chronic obstructive pulmonary disease.